(DDRT) (DDRT) Stock Price, News & Analysis

Company Overview

Enochian Biosciences, Inc. engages in the development of genetically modified cellular and immune-therapy technologies for treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev on January 18, 2011 and is headquartered in Los Angeles, CA.

Key Stats

• Today's Range: $6.00 to $6.05
• 50-Day Range: N/A
• 52-Week Range: $1.05 to $7.10
• Volume: 30,875 shs
• Average Volume: 12,872 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

DDRT Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of (DDRT) own?

Based on aggregate information from My MarketBeat watchlists, some other companies that (DDRT) investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX) and Ampio Pharmaceuticals (AMPE).

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Finance
• Industry: Financial Conglomerates
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:DDRT
• CIK: 1527728
• Web: www.dandrit.com
• Phone: (786) 888-1685
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A